{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PFSA","limit":50},"count":50,"signals":[{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":90,"context":"t the direction of the FDA or another governmental authority, could have a negative impact on us. | | | | Quality problems could lead to recalls or safety alerts, reputational harm, and could have a material adverse effect on our business, results of operations, financial condition and cash flows. | | **** **Risks Related to Intellectual Property Protection and Use** | | We may become subject to claims of infringement","filed_date":"2026-02-17","accession":"0001213900-26-016936","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"and chief financial officer. Imaging Advantage was acquired by Envision in 2015. In 2014, he served as the executive vice president and chief financial officer for Questcor Pharmaceuticals which was acquired by Mallinckrodt in a $5.6B transaction. Mr.Asarpota also spent a decade at Life Technologies, a global life sciences company where he was responsible for helping scale the organization, driving growth through organic and M","filed_date":"2026-02-17","accession":"0001213900-26-016936","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":89,"context":"r shareholders in the public market could cause the market price for the Common Stock to decline. | | | | Quality problems could lead to recalls or safety alerts, reputational harm, and could have a material adverse effect on our business, results of operations, financial condition and cash flows. | | | | We may become subject to claims of infringement or misappropriation of the intellectual property rights of others","filed_date":"2026-02-13","accession":"0001213900-26-016096","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":15,"context":"and chief financial officer. Imaging Advantage was acquired by Envision in 2015. In 2014, he served as the executive vice president and chief financial officer for Questcor Pharmaceuticals which was acquired by Mallinckrodt in a $5.6B transaction. Mr. Asarpota also spent a decade at Life Technologies, a global life sciences company where he was responsible for helping scale the organization, driving growth through organic and","filed_date":"2026-02-13","accession":"0001213900-26-016096","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":26,"context":"aq listing requirements. **Significant Risks and Uncertainties** The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Companys future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinica","filed_date":"2025-11-19","accession":"0001213900-25-112723","full_text":"https://origin.rootz.global/static/filing/0001213900-25-112723.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":6,"context":"oving certain advisory proposals related to the amended and restated Certificate of Incorporation, (iii) approved the issuance of new shares of the Companys Common Stock as merger consideration, (iv) elected new directors, and (v) approved new employee incentive plans. In connection with the meeting, the holders of 52,784 Public Shares properly exercised their right to redeem, with 5,295,527 shares of Common Stock re","filed_date":"2025-08-14","accession":"0001213900-25-076861","full_text":"https://origin.rootz.global/static/filing/0001213900-25-076861.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"joint or several, whether now existing or hereafter arising and however acquired and whether or not known, asserted, direct, contingent, liquidated, due, consequential, actual, punitive or treble. **Material Adverse Effect** means material adverse effect on, or change in, (a) the legality, validity or enforceability of any portion of any Transaction Document or any transaction contemplated therein, (b) the operations,","filed_date":"2025-07-28","accession":"0001213900-25-067855","full_text":"https://origin.rootz.global/static/filing/0001213900-25-067855.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":19,"context":"initial business combination with only a single entity, our lack of diversification may: | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and | | | | cause us to depend on the marketing and sale of a single product or limited number of products or","filed_date":"2025-03-31","accession":"0001013762-25-004396","full_text":"https://origin.rootz.global/static/filing/0001013762-25-004396.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":7,"context":"icers and Directors** Our board of directors consists of five directors. We may not hold an annual meeting of stockholders until after we consummate our initial business combination. Our officers are elected by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it","filed_date":"2025-03-31","accession":"0001013762-25-004396","full_text":"https://origin.rootz.global/static/filing/0001013762-25-004396.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"joint or several, whether now existing or hereafter arising and however acquired and whether or not known, asserted, direct, contingent, liquidated, due, consequential, actual, punitive or treble. **Material Adverse Effect** means material adverse effect on, or change in, (a) the legality, validity or enforceability of any portion of any Transaction Document or any transaction contemplated therein, (b) the operations,","filed_date":"2025-02-19","accession":"0001213900-25-014987","full_text":"https://origin.rootz.global/static/filing/0001213900-25-014987.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"initial business combination with only a single entity, our lack of diversification may: | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and | | | | cause us to depend on the marketing and sale of a single product or limited number of products or","filed_date":"2024-02-26","accession":"0001213900-24-016600","full_text":"https://origin.rootz.global/static/filing/0001213900-24-016600.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":9,"context":"nitial business combination with only a single entity, our lack of diversification may: | | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and | | | | | cause us to depend on the marketing and sale of a single product or limited number of products o","filed_date":"2023-03-06","accession":"0001213900-23-017591","full_text":"https://origin.rootz.global/static/filing/0001213900-23-017591.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":9,"context":"nitial business combination with only a single entity, our lack of diversification may: | | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and | | | | | cause us to depend on the marketing and sale of a single product or limited number of products o","filed_date":"2022-03-18","accession":"0001213900-22-013308","full_text":"https://origin.rootz.global/static/filing/0001213900-22-013308.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":87,"match_count":4,"context":"oving certain advisory proposals related to the amended and restated Certificate of Incorporation, (iii) approved the issuance of new shares of the Companys Common Stock as merger consideration, (iv) elected new directors, and (v) approved new employee incentive plans. In connection with the meeting, the holders of 52,784 Public Shares properly exercised their right to redeem, with 5,295,527 shares of Common Stock re","filed_date":"2025-06-13","accession":"0001213900-25-054386","full_text":"https://origin.rootz.global/static/filing/0001213900-25-054386.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"pre-diabetes management, lifestyle coaching platforms/apps, and health and wellness apps. Profusa bases this hypothesis on the belief that clinically relevant data, in real time, is central to these AI-driven platforms ability to deliver automated meaningful insights to the users. In telemedicine, a physician/patient interaction would be more efficient if real time biochemistry parameters are available during the","filed_date":"2026-02-17","accession":"0001213900-26-016936","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"pre-diabetes management, lifestyle coaching platforms/apps, and health and wellness apps. Profusa bases this hypothesis on the belief that clinically relevant data, in real time, is central to these AI-driven platforms ability to deliver automated meaningful insights to the users. In telemedicine, a physician/patient interaction would be more efficient if real time biochemistry parameters are available during the","filed_date":"2026-02-13","accession":"0001213900-26-016096","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":71,"match_count":2,"context":"uisition of Profusa. The Company has a wholly-owned subsidiary, NV Profusa Merger Sub Inc. (Merger Sub), a Delaware corporation incorporated on October 13, 2022, formed solely in contemplation of the Merger with Profusa (See Note 6). Merger Sub has not commenced any operations and has only nominal assets and no liabilities or contingent liabilities, nor any outstanding commitments other than in connection wi","filed_date":"2024-12-17","accession":"0001213900-24-109808","full_text":"https://origin.rootz.global/static/filing/0001213900-24-109808.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":71,"match_count":2,"context":"uisition of Profusa. The Company has a wholly-owned subsidiary, NV Profusa Merger Sub Inc. (Merger Sub), a Delaware corporation incorporated on October 13, 2022, formed solely in contemplation of the Merger with Profusa (See Note 6). Merger Sub has not commenced any operations and has only nominal assets and no liabilities or contingent liabilities, nor any outstanding commitments other than in connection wi","filed_date":"2024-11-15","accession":"0001213900-24-098671","full_text":"https://origin.rootz.global/static/filing/0001213900-24-098671.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":68,"match_count":6,"context":"entered into an option agreement to acquire G3 on July 31, 2026, which superseded the abovementioned term sheet. *Changes in Directors and Executive Officers* Effective July 21, 2026, Jack Stover was appointed Executive Chairman and Chief Executive Officer and Ben Hwang was appointed President. On July 26, 2026, Mr. Hwang resigned from the Board while continuing to serve as President, and Liviu Goldenberg was appointed as an independe","filed_date":"2026-08-19","accession":"0001213900-26-091696","full_text":"https://origin.rootz.global/static/filing/0001213900-26-091696.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":67,"match_count":4,"context":"curities were suspended from trading and delisted from Nasdaq on December 27, 2024, following receipt of a delisting determination letter from Nasdaq on December 20, 2024. This could have significant material adverse consequences on us and our securities, including that it will negatively impact our ability to complete a business combination, will limit investors ability to make transactions in our securities and could subje","filed_date":"2025-03-07","accession":"0001213900-25-021270","full_text":"https://origin.rootz.global/static/filing/0001213900-25-021270.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":61,"match_count":2,"context":"uisition of Profusa. The Company has a wholly-owned subsidiary, NV Profusa Merger Sub Inc. (Merger Sub), a Delaware corporation incorporated on October 13, 2022, formed solely in contemplation of the Merger with Profusa (See Note 6). Merger Sub has not commenced any operations and has only nominal assets and no liabilities or contingent liabilities, nor any outstanding commitments other than in connection wi","filed_date":"2024-10-09","accession":"0001213900-24-086609","full_text":"https://origin.rootz.global/static/filing/0001213900-24-086609.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":60,"match_count":5,"context":"under Delaware law for each such transaction. | Type of Transaction | | Whether Stockholder Approval is Required | | | Purchase of assets | | No | | | Purchase of stock of target not involving a merger with the company | | No | | | Merger of target into a subsidiary of the company | | No | | | Merger of the company with a target | | Yes | | Under Nasdaqs listing rules, stockholder approval would be","filed_date":"2024-02-26","accession":"0001213900-24-016600","full_text":"https://origin.rootz.global/static/filing/0001213900-24-016600.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":54,"match_count":3,"context":"of September 30, 2025 and December 31, 2024, respectively. We expect our costs to increase in future periods as we continue to expend substantial resources on research and development, expansion into new markets, marketing and general administration (including expenses related to being a public company). The net losses we incur may fluctuate significantly from quarter to quarter. Our long-term success is de","filed_date":"2026-02-13","accession":"0001213900-26-016096","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":54,"match_count":3,"context":"ent under government grants. Significant Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Companys future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinica","filed_date":"2026-08-19","accession":"0001213900-26-091696","full_text":"https://origin.rootz.global/static/filing/0001213900-26-091696.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":48,"match_count":6,"context":"ent, on the ability of our partners to successfully commercialize their systems or products. Any factors that may limit our partners ability to achieve widespread adoption of their systems, including competitive pressures, technological breakthroughs for the treatment or prevention of diabetes, adverse regulatory or legal actions relating to their products, or changes in reimbursement rates or policies of third-party","filed_date":"2026-02-17","accession":"0001213900-26-016936","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":48,"match_count":6,"context":"ent, on the ability of our partners to successfully commercialize their systems or products. Any factors that may limit our partners ability to achieve widespread adoption of their systems, including competitive pressures, technological breakthroughs for the treatment or prevention of diabetes, adverse regulatory or legal actions relating to their products, or changes in reimbursement rates or policies of third-party","filed_date":"2026-02-13","accession":"0001213900-26-016096","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":40,"match_count":5,"context":"der Delaware law for each such transaction. | Type of Transaction | | Whether Stockholder Approval is Required | | | Purchase of assets | | No | | | Purchase of stock of target not involving a merger with the company | | No | | | Merger of target into a subsidiary of the company | | No | | | Merger of the company with a target | | Yes | | Under Nasdaqs listing rules, stockholder approval would","filed_date":"2023-03-06","accession":"0001213900-23-017591","full_text":"https://origin.rootz.global/static/filing/0001213900-23-017591.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":32,"match_count":4,"context":"der Delaware law for each such transaction. | Type of Transaction | | Whether Stockholder Approval is Required | | | Purchase of assets | | No | | | Purchase of stock of target not involving a merger with the company | | No | | | Merger of target into a subsidiary of the company | | No | | | Merger of the company with a target | | Yes | | Under Nasdaqs listing rules, stockholder approval would","filed_date":"2022-03-18","accession":"0001213900-22-013308","full_text":"https://origin.rootz.global/static/filing/0001213900-22-013308.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":31,"match_count":2,"context":"laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application also may change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our b","filed_date":"2022-05-12","accession":"0001213900-22-025671","full_text":"https://origin.rootz.global/static/filing/0001213900-22-025671.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":24,"match_count":3,"context":"of September 30, 2025 and December 31, 2024, respectively. We expect our costs to increase in future periods as we continue to expend substantial resources on research and development, expansion into new markets, marketing and general administration (including expenses related to being a public company). The net losses we incur may fluctuate significantly from quarter to quarter. Our long-term success is de","filed_date":"2026-02-17","accession":"0001213900-26-016936","full_text":"https://origin.rootz.global/static/filing/0001213900-26-016936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":21,"match_count":2,"context":"| Directors are elected by a plurality of the votes cast at the Annual Meeting. “Plurality” means that the nominees who receive the largest number of votes cast “FOR” are elected as directors. As a result, any shares not voted “FOR” a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee’s favor an","filed_date":"2024-03-11","accession":"0001213900-24-021244","full_text":"https://origin.rootz.global/static/filing/0001213900-24-021244.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":18,"match_count":1,"context":"ock Split, then we will be subject to immediate delisting from Nasdaq. If the results of the Reverse Stock Split are different than expected and we are delisted from Nasdaq, the delisting will have a significant adverse impact on our business, operations and financial condition. While we expect the Reverse Stock Split to increase our stock price and allow us to regain compliance with the Minimum Bid Price requirement and r","filed_date":"2026-01-02","accession":"0001213900-26-000004","full_text":"https://origin.rootz.global/static/filing/0001213900-26-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":18,"match_count":1,"context":"iness combination . Subsequent to the completion of our business combination, we may be required to take write - downs or write - offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and our stock price, which could cause you to lose some or all of your investment . We may issue notes or other debt securities, or otherwise incur s","filed_date":"2022-11-10","accession":"0001213900-22-071254","full_text":"https://origin.rootz.global/static/filing/0001213900-22-071254.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"ons. **Inflation, Monetary Response, and Economic Impacts** The world economy is experiencing stubbornly high inflation, a challenge not faced for decades. Following the global financial crisis, with inflationary pressures muted, interest rates were extremely low for years and investors became accustomed to low volatility. The resulting easing of financial conditions supported economic growth, but it also contributed","filed_date":"2025-11-19","accession":"0001213900-25-112723","full_text":"https://origin.rootz.global/static/filing/0001213900-25-112723.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":16,"match_count":2,"context":"amount recorded is based on the fair value of the cash received. The Company records ELOC transactions based on the actual cash received for each draw, as this is clearly measurable and traceable. **Merger with Northview Acquisition Company** The Company accounted for the merger with Northview as a reverse recapitalization. A reverse recapitalization occurs when the legal acquirer (the public shell company)","filed_date":"2025-11-19","accession":"0001213900-25-112723","full_text":"https://origin.rootz.global/static/filing/0001213900-25-112723.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":16,"match_count":2,"context":"althcare innovation. The Company has a wholly-owned subsidiary, NV Profusa Merger Sub Inc. (Merger Sub), a Delaware corporation incorporated on October 13, 2022, formed solely in contemplation of the Merger with Profusa (See Note 6). Merger Sub has not commenced any operations and has only nominal assets and no liabilities or contingent liabilities, nor any outstanding commitments other than in connection wi","filed_date":"2023-11-20","accession":"0001213900-23-088706","full_text":"https://origin.rootz.global/static/filing/0001213900-23-088706.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":16,"match_count":2,"context":"althcare innovation. The Company has a wholly-owned subsidiary, NV Profusa Merger Sub Inc. (Merger Sub), a Delaware corporation incorporated on October 13, 2022, formed solely in contemplation of the Merger with Profusa (See Note 6). Merger Sub has not commenced any operations and has only nominal assets and no liabilities or contingent liabilities, nor any outstanding commitments other than in connection wi","filed_date":"2023-08-14","accession":"0001213900-23-067194","full_text":"https://origin.rootz.global/static/filing/0001213900-23-067194.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":16,"match_count":2,"context":"althcare innovation. The Company has a wholly-owned subsidiary, NV Profusa Merger Sub Inc. (Merger Sub), a Delaware corporation incorporated on October 13, 2022, formed solely in contemplation of the Merger with Profusa (See Note 6). Merger Sub has not commenced any operations and has only nominal assets and no liabilities or contingent liabilities, nor any outstanding commitments other than in connection wi","filed_date":"2023-05-17","accession":"0001213900-23-040837","full_text":"https://origin.rootz.global/static/filing/0001213900-23-040837.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":13,"match_count":1,"context":"usy four months for the team, and we are proud of our achievements in such a short period of time. In the third quarter, we achieved a significant milestone for the company with the completion of our merger with NorthView Acquisition Corporation. We recapitalized our balance sheet, reducing net debt from $34 million to $14 million as of October 31, 2025. Since the closing of the merger on July 11, 2025, we h","filed_date":"2025-11-20","accession":"0001213900-25-112761","full_text":"https://origin.rootz.global/static/filing/0001213900-25-112761.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":13,"match_count":1,"context":"ome of this uncertainty. **Significant Risks and Uncertainties** The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Companys future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinica","filed_date":"2025-08-15","accession":"0001213900-25-076867","full_text":"https://origin.rootz.global/static/filing/0001213900-25-076867.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":13,"match_count":1,"context":"this uncertainty. ** ** **Significant Risks and Uncertainties** The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Companys future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinica","filed_date":"2025-07-18","accession":"0001213900-25-065686","full_text":"https://origin.rootz.global/static/filing/0001213900-25-065686.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":13,"match_count":1,"context":"ies trade on the Over the Counter (OTC) market, which could limit investors ability to make transactions in our securities and subject us to additional trading restrictions, we could face significant material adverse consequences, including. | | a determination that our public shares are a penny stock, which will require brokers trading in the public shares to adhere to more stringent rules and possibly result in a reduced","filed_date":"2025-06-13","accession":"0001213900-25-054386","full_text":"https://origin.rootz.global/static/filing/0001213900-25-054386.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":13,"match_count":1,"context":"he Counter (OTC) market, which could limit investors ability to make transactions in our securities and subject us to additional trading restrictions. If this were to occur, we would face significant material adverse consequences, including. | | a determination that our public shares are a penny stock, which will require brokers trading in the public shares to adhere to more stringent rules and possibly result in a reduced","filed_date":"2024-12-17","accession":"0001213900-24-109808","full_text":"https://origin.rootz.global/static/filing/0001213900-24-109808.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"our common stock by: •        each of our directors; •        each of our named executive officers; •        all directors and executive officers as a group; and •        ","filed_date":"2026-01-02","accession":"0001213900-26-000004","full_text":"https://origin.rootz.global/static/filing/0001213900-26-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":8,"match_count":1,"context":"Fred Knechtel, CFO of Profusa, commented, To deliver value to shareholders and provide the company with adequate capital to achieve near-term revenue goals and define long-term growth strategies, we transformed the companys balance sheet by raising capital and reducing outstanding indebtedness. We intend to further reduce debt to minimal levels in the next few quarters by exercising flexibility with debt to equity conv","filed_date":"2025-11-20","accession":"0001213900-25-112761","full_text":"https://origin.rootz.global/static/filing/0001213900-25-112761.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"ny may issue to the Participating Securityholders an aggregate of 3,875,000 shares of Company Common Stock (the Milestone Earnout Shares) during the respective earnout periods in equal quarterly installments upon achievement of the following four Milestone Events: | | Milestone I Earnout Rights: share price of Company Common Stock is equal to or greater than $12.50 for any 20 trading days during any","filed_date":"2025-11-19","accession":"0001213900-25-112723","full_text":"https://origin.rootz.global/static/filing/0001213900-25-112723.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"our common stock by: •        each of our directors; •        each of our named executive officers; •        all directors and executive officers as a group; and •        ","filed_date":"2025-09-23","accession":"0001213900-25-090286","full_text":"https://origin.rootz.global/static/filing/0001213900-25-090286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"growth_inflection","strength":8,"match_count":1,"context":"otal moment, said Mr. ORourke. Profusas biosensor technology has the potential to transform how we understand and monitor human health. I look forward to working with the Board and leadership team to accelerate growth, support commercialization, and maximize shareholder value. Mr. Knechtel has led finance and operations from start-ups to publicly traded large cap companies. As CFO, he guided organizations operatin","filed_date":"2025-08-19","accession":"0001213900-25-078539","full_text":"https://origin.rootz.global/static/filing/0001213900-25-078539.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"NVAC). Peter ORourke, former Acting U.S. Secretary of Veterans Affairs (VA), has joined the Board of Directors as lead independent director, and Fortune 500 financial executive Fred Knechtel has been named Chief Financial Officer. Profusa is at an inflection point as we prepare to bring our transformative biosensor platform to global markets, said Ben Hwang, Ph.D., CEO of Profusa. Peter brings extensive leadership experience,","filed_date":"2025-08-19","accession":"0001213900-25-078539","full_text":"https://origin.rootz.global/static/filing/0001213900-25-078539.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFSA","company":"Profusa, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":8,"match_count":1,"context":"our common stock by: •        each of our directors; •        each of our named executive officers; •        all directors and executive officers as a group; and •        ","filed_date":"2025-08-18","accession":"0001213900-25-077850","full_text":"https://origin.rootz.global/static/filing/0001213900-25-077850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"9346f88b1b1e838ded7205a8cb069c85b90c769961ceb2866ff96bea91acf527","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"e08dc133bdde6cb5f8f0a366d99a7571b81ff48258f8b111de6bc3b7b7b6e535","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":17,"hourly_limit":500,"remaining":483,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}